The US Food and Drug Administration approved the Charité artiÀ cial disc on October 26, 2004. This approval was based on an extensive analysis and review process; 20 years of disc usage worldwide; and the results of a prospective, randomized, controlled clinical trial that compared lumbar artiÀ cial disc replacement to fusion. The results of the investigational device exemption (IDE) study led to a conclusion that clinical outcomes following lumbar arthroplasty were at least as good as outcomes from fusion.
INTRODUCTION
Low-back pain is the second most common reason (after the common cold) for visits to primary-care physicians.
1 Up to 80% of individuals in the United States will experience low-back pain at some point in their lives.
2 Approximately 5% of this group will progress to a condition of chronic back pain, much of which is attributable to degenerative disc disease (DDD), the leading cause of pain and disability in the United States.
3,4 The exact incidence and prevalence of DDD is unknown, because many cases are asymptomatic and therefore do not trigger physician visits. 5 Examples of non-operative care for chronic low-back pain include allowing time for a natural healing mechanism to work, rehabilitation of the patient may require a similar time to be completed to achieve the maximum successful clinical beneÀ t of the procedure.
Though lumbar artiÀ cial disc technology has been used commercially in Europe since 1987, the À rst disc implanted in the United States at the Texas Back Institute (Plano, Tex) by Scott Blumenthal was in March 2000 at the start of the US Food and Drug Administration (FDA) investigational device exemption (IDE) trial. Therefore, lumbar arthroplasty is a relatively new procedure to treat lumbar DDD in the United States. The hypothesized beneÀ ts of arthroplasty over fusion procedures with signiÀ cant clinical beneÀ t include (1) reduction or elimination of disc-derived (also known as discogenic) pain; (2) restoration and maintenance of normal segmental range of motion and sagittal balance; and (3) potential reduction or retardation of progressive adjacent-level DDD, which necessitates further surgical intervention involving not only reducing the forces and angulation of the adjacent level compared with a fusion but also normalizing the adjacent level biomechanics.
9
On October 26, 2004, the FDA approved the world's À rst lumbar artiÀ cial disc, the Charité artiÀ cial disc (DePuy Spine, Raynham, Mass), for use in the United States. 10 In doing so, the FDA followed the recommendation of its expert Orthopaedic and Rehabilitation Devices Panel, which on June 2, 2004, unanimously recommended approval.
11 The FDA decision was based on the results of a prospective, randomized, controlled clinical trial that compared lumbar artiÀ cial disc replacement to anterior lumbar interbody fusion (ALIF) and on 20 years of worldwide surgical experience. FDA approval meant that the manufacturer could market the device as safe and effective for the treatment of single-level lumbar DDD in indicated patients at either the L4-5 or L5-S1 level.
This clinical trial was the À rst in the history of spine surgery to compare two different surgical treatments for lumbar DDD according to a multicenter, prospective, randomized, controlled study design. The results of the study were published in peerreviewed journals, including Journal of Neurosurgery in September 2004 9 and Spine in July 2005. 12,13 Because of the prospectively speciÀ ed non-inferiority design of the study and the complex FDA-required success/failure criteria, the primary conclusion of the study for FDA labeling purposes was that treatment with artiÀ cial disc replacement was clinically at least as good as a fusion procedure.
I present here new level I medical evidence that surgical treatment with single-level arthroplasty is not only "at least as good as" a fusion procedure, as the FDA label states, but that reduction in pain and disability improvement are highly statistically superior in patients receiving treatment with lumbar arthroplasty compared to both baseline and an anterior fusion procedure. A more rapid decrease in pain and disability (postoperative healing/recovery) was also noted in the Charité group compared to the fusion group.
MATERIALS AND METHODS
A multicenter, prospective, randomized, controlled trial was performed under an FDA-approved protocol (IDE# G990303). Local institutional review board approval was obtained at all 14 study sites, and all subjects enrolled in the study gave written informed consent. The trial incorporated a non-inferiority design with a 2:1 randomization: treatment with artiÀ cial disc replacement versus the control, a fusion procedure. Enrollment in the study constituted 71 subjects in an initial nonrandomized treatment phase (approximately 5 subjects per site) and then a total of 304 subjects in the randomized phase: 205 in the treatment group and 99 in the control group. Subjects in the control group underwent an ALIF procedure with BAK threaded fusion cages (Zimmer Spine, Minneapolis, Minn) and bone graft. Subjects were assessed clinically and radiographically before surgery, 6 weeks after surgery, and then at 3, 6, 12, and 24 months after surgery. Demographics, inclusion/exclusion criteria, subject accountability, clinical outcomes, and all other detailed study information conforming to the CONSORT checklist were previously described by Blumenthal et al. 12 The Oswestry Disability Index (ODI) is a 10-question validated measure (score 0-100) of disability and pain among the population with low-back pain.
14 Subjects were required to complete an ODI questionnaire and a 0-100 Visual Analog Scale (VAS) pain questionnaire preoperatively and at each follow-up visit.
STATISTICAL METHODS
The statistical analysis of the ODI and VAS scores performed for the FDA and reported by Blumenthal et al., required the use of the Student's t test. This methodology was prespeciÀ ed in the statistical plan of the protocol (1) before FDA approval of the protocol, (2) before subsequent subject enrollment, and (3) before the results/distributions of the data were known. In the FDA-approved protocol the methodology could not be altered post hoc for FDA labeling claims. Using Student's ttest, mean ODI and VAS scores were signiÀ cantly better in the treatment group compared with the control group at all followup time points except for the 2-year follow-up.
12 These results, combined with the non-inferiority study design, resulted in the primary conclusion of the study: that treatment with artiÀ cial disc replacement is at least as good as a fusion procedure in properly indicated patients.
However, Student's t test, by deÀ nition, assumes a normal distribution of data. Therefore, Student's t test is simply not the appropriate test with which to analyze non-normally distributed data. The ODI and VAS scores reasonably approximated a normal distribution at baseline. At the 2-year follow-upthe endpoint of the study-the distributions were heavily nonsymmetric, skewed, and clearly not normally distributed ( Figure 1 ). Using Student's t test might be compared to driving a car on tires designed to be inÁ ated to 35 psi, but only inÁ ating them to 10 psi.
A more appropriate statistical test for analysis of nonnormally distributed data would be a nonparametric test such as the Wilcoxon rank sum test, which is appropriate for a non-normal data distribution. I performed a separate analysis of the ODI and VAS scores using the Wilcoxon rank sum test in which all subjects enrolled in both the nonrandomized and randomized phases of the treatment group (n = 276) were compared to the study control group (the complete FDA IDE dataset). The data utilized for this analysis were the same data submitted to the FDA as part of the postmarketing application submission-this was not a subset analysis. The results were veriÀ ed by an independent third party (Stat Tech Services, Chapel Hill, NC) using the SAS version 8.2 statistical software package (SAS Institute, Cary, NC).
Figure 1
Distribution of VAS pain scores and ODI disability scores for all subjects (i.e., both treatment and control groups). A reasonable approximation of a normal distribution of scores is evident at baseline. However, at 2-year follow-up the distributions are not normal but skew towards the low cut-off end of both scales, indicating a favorable clinical response.
RESULTS
Both the ODI and VAS scores had almost identical initial mean values for each of the 2 groups (treatment and control). Thus, the randomization worked in this study and no baseline corrections were necessary or used in the analysis of this data.
The nonparametric analysis of ODI and VAS scores demonstrated that subjects enrolled in both the treatment and the control groups had highly signiÀ cantly lower scores at all time points compared to baseline, including the 2-year followup (P < .001). The improved scores in both groups were (1) sustained over the 2-year period, (2) monotonically decreasing, and (3) more than twice the difference considered to be of minimum clinical signiÀ cance.
15 This triad makes a placebo effect of surgery an unlikely explanation for the observed improvement. Furthermore, inspection of the recovery curves reveals signiÀ cant improvement at 6 weeks with maintenance out to 2 years (Figures 2, 3) .
Patients in the treatment group attained a greater proportion of the total 2-year recovery in this early phase of the postoperative period in both clinical indexes. Additionally, signiÀ cantly lower scores occurred in the Charité artiÀ cial disc group compared to the control fusion group at all postoperative time points, including the 2-year follow-up (P < .05). These results demonstrate superiority of arthroplasty over fusion in indicated patients, according to these key clinical measures, and a major improvement from baseline in both treatment groups. The control group scores closely followed the results of the BAK cage IDE study described by Kuslich et al. 16 
DISCUSSION
Given the distribution of the ODI and VAS scores at 2 years as shown in Figure 1 , it is clear that a nonparametric test is the appropriate statistical test for analyzing the ODI and VAS data from the Charité artiÀ cial disc clinical trial. This new analysis does not and cannot change the primary FDA study conclusion: that arthroplasty is "at least as good as" a fusion procedure. This limitation of labeling claims occurred because the FDA study was conducted with a non-inferiority design with prespeciÀ ed criteria for clinical success. Furthermore, FDA claims of clinical superiority cannot emanate from non-inferiority studies that are not a priori sufÀ ciently powered to demonstrate superiority of one treatment over another.
However, improvement in ODI score was a primary clinical endpoint of this study and improvement in VAS score was a secondary clinical endpoint. These 2 clinical outcome measures are the most relied-upon measures of clinical outcome following low-back surgery. There is no doubt, following this analysis, that subjects receiving arthroplasty attained superiority in improved pain and disability levels compared with baseline levels and at Mean ODI disability scores at baseline and at each protocol-speci¿ ed follow-up time point through 2 years. The dotted line indicates the ODI score necessary for minimum clinical improvement, 10 points.
14 (a) Mean scores for 276 subjects in the Charité arti¿ cial disc treatment group. There was a signi¿ cant difference in level of disability at all time points compared to baseline (P < .001), Wilcoxon rank sum test. (b) Mean scores for subjects in the treatment group compared to 99 enrolled subjects in the control group. There was a signi¿ cant difference in the treatment group with respect to disability, compared to the control group at all postoperative time points (P < .05), Wilcoxon rank sum test.
(a) (b)
Figure 2 all follow-up time points and attained superiority in pain and disability levels compared to fusion, the historical standard of care when the study began. 27, 28 written before publication of the US trial (level IV medical evidence) as the primary reason why arthroplasty is not a reasonable treatment for discogenic low-back pain. Yet other more favorable long-term results in large patient cohorts (level IV medical evidence) are often only offhandedly considered. [29] [30] [31] [32] Lumbar arthroplasty with the Charité artiÀ cial disc has been performed outside the United States for more than 20 years and, as McAfee 33 eloquently pointed out, the overwhelming majority of the early disc arthroplasty cases were performed with widely variable indications; basic, rudimentary instrumentation; different sizing options; nonexistent diagnostic testing; and a lack of fundamental understanding of lumbar spine biomechanics. These early issues and failures were well known to the clinical trial investigators at the time the FDA IDE study protocol was developed. In fact, it was this knowledge of the previous successes and failures that led to the inclusion/exclusion criteria and the surgical technique used in the FDA IDE study. Thus, the FDA IDE study was designed, based upon the earlier experience, to provide level I medical evidence of the efÀ cacy and safety of treatment with lumbar arthroplasty learned from the earlier experience, and to better deÀ ne the appropriate patient selection, surgical technique, and implant sizing. The previous lumbar artiÀ cial disc clinical information has been analyzed and clinical and surgical techniques have been reÀ ned through the 20-year history of the device. If this historical review of the previous series had not occurred, then the clinically superior results presented here would not have been possible. Using the historical data and clinical experience to criticize the FDA IDE results in a vacuum, without considering the advancements described above, seems unwarranted and unscientiÀ c.
As for lack of safety, another continuing cause for criticism of arthroplasty, the same historical literature is often cited without proper context and without any relevance to today's indications, implants, instrumentation, and knowledge. Contemporary information about complications in today's arthroplasty patients has been presented at dozens of medical meetings over the past 3 years and has been published.
12,34-36
Mean VAS pain scores at baseline and at each protocol-speci¿ ed follow-up time point through 2 years. The dotted line indicates the VAS score necessary for minimum clinical improvement, 19 points.
14 (a) Mean scores for 276 subjects in the Charité arti¿ cial disc treatment group. There was a signi¿ cant difference in pain at all time points compared to baseline (P < .001), Wilcoxon rank sum test. (b) Mean scores for subjects in the treatment group compared to the 99 enrolled subjects in the control group. There was a signi¿ cant difference in the treatment group with respect to pain, compared to the control group at all postoperative points (P < .05), Wilcoxon rank sum test.
Figure 3
Revision rates for fusion are just as high or higher than for disc replacement. 36, 37 No evidence exists that the incidence of complications with or without revision is higher in arthroplasty patients compared with fusion patients. However, differences exist in the types of potential complications.
Before the 1970s-1980s, fusion was the standard of care for surgical treatment of degenerative conditions of the hip and knee. This fusion standard was replaced in the ensuing years with artiÀ cial joint arthroplasty, which today is the standard of care for surgical treatment of these conditions in indicated patients. Often cited as the grandfather of modern hip arthroplasty, the early ideas of John Charnley for avoiding fusion of the hip [38] [39] [40] were not readily accepted.
41,42 Though Charnley's work began in the late 1950s, the À rst hip replacement in the United States was not performed until 1969, with the À rst appearance in the US literature in 1970. 43 Modern disc replacement has taken a similar track, with the third-generation Charité artiÀ cial disc having been developed and used in Europe as early as 1987 44 and used in the À rst such procedure performed in the United States only in March 2000.
As noted earlier, Deyo et al. have denounced both non-operative and operative treatment for low-back pain, including fusion and now disc replacement. What else is there for the patient with chronic low-back pain? Despite Deyo's criticism, there are in fact multiple prospective, multicenter low-back fusion studies that describe good results and that have been published in the peerreviewed literature. 16, [45] [46] [47] All of these studies were performed under FDA-approved protocols with narrow indications, as was the Charité clinical trial.
Highly signiÀ cant improvements in pain and level of disability compared to baseline in indicated disc replacement patients is not in question. Superior pain reduction and reduced disability level compared to the current standard of care are not in question. Critics of surgical intervention for patients with low-back pain decry the lack of level I data, yet when level I data demonstrating superior outcomes are produced, the surgical intervention is still criticized as "too new," "ineffective," or "unsafe" despite extraordinary evidence to the contrary. In the face of level I data, such critics use lower levels of evidence in an attempt to essentially cancel out the results of a level I study. But level II, III, IV, and V data, by deÀ nition, do not trump level I data, and lower levels of published data exist for every treatment in medicine. If lower levels of data are allowed to trump Level I data, then nothing in medicine would be proven safe and effective, and if that is the case, why perform Level I studies at all? Disc replacement in the low back is not for every patient with chronic low-back pain. Currently in the United States, disc replacement is narrowly indicated to patients with painful DDD at 1 level (L4-5 or L5-S1); who have no contraindications such as multilevel disease, scoliosis, or instability; and who fail at least 6 months of non-operative treatment. In my practice area, approximately 1 in 5000 patients with low-back pain are indicated for disc replacement after applying the indications and contraindications for the procedure. Thus, disc replacement is not being "sold" by physicians or by industry as a cure for lowback pain, though the lay press and Wall Street investors often jump to that conclusion.
As of this writing, a majority of private payers are not covering lumbar arthroplasty, a treatment backed by level I clinical data that demonstrates superior pain and disability improvement compared to baseline and to a fusion procedure. This leaves the patient with a choice between having an inferior surgical procedure covered by insurance or waiting in pain and disability for an indeÀ nite period, hoping for a reversal in a payer's coverage decision. All of this takes the decision of treatment out of the hands of physicians and patients and places it in the capricious hands of government and third-party payers. As a result, only a small number of À nancially well-off patients will be able to receive this FDA-approved treatment. But the middle classand more importantly the working and nonworking poor-will not have access to an FDA-approved treatment in the United States. Further, though a CPT (current procedural terminology) code (22857) now exists for the procedure, the payment ($1382) is decidedly inadequate compared with that for a less technically demanding ALIF procedure ($1975) , a disparity that serves as a disincentive to surgeons to perform lumbar arthroplasty in indicated patients.
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